MX2020012366A - Biarilamidas con grupos de azucar modificados para el tratamiento de enfermedades asociadas con la trayectoria de la proteina de choque de calor. - Google Patents

Biarilamidas con grupos de azucar modificados para el tratamiento de enfermedades asociadas con la trayectoria de la proteina de choque de calor.

Info

Publication number
MX2020012366A
MX2020012366A MX2020012366A MX2020012366A MX2020012366A MX 2020012366 A MX2020012366 A MX 2020012366A MX 2020012366 A MX2020012366 A MX 2020012366A MX 2020012366 A MX2020012366 A MX 2020012366A MX 2020012366 A MX2020012366 A MX 2020012366A
Authority
MX
Mexico
Prior art keywords
modified sugar
sugar groups
treatment
heat shock
diseases associated
Prior art date
Application number
MX2020012366A
Other languages
English (en)
Spanish (es)
Inventor
Christopher F Bender
Gary Bolton
Chitase Lee
Melean Visnick
Xin Jiang
Bradley CAPRATHE
Original Assignee
Reata Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reata Pharmaceuticals Inc filed Critical Reata Pharmaceuticals Inc
Publication of MX2020012366A publication Critical patent/MX2020012366A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/01—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
    • C07C59/11—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C07D309/12—Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/04—Carbocyclic radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H9/00—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
    • C07H9/02—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical the hetero ring containing only oxygen as ring hetero atoms
    • C07H9/04—Cyclic acetals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyrane Compounds (AREA)
MX2020012366A 2018-05-14 2019-05-14 Biarilamidas con grupos de azucar modificados para el tratamiento de enfermedades asociadas con la trayectoria de la proteina de choque de calor. MX2020012366A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862671047P 2018-05-14 2018-05-14
PCT/US2019/032292 WO2019222269A1 (en) 2018-05-14 2019-05-14 Biaryl amides with modified sugar groups for treatment of diseases associated with heat shock protein pathway

Publications (1)

Publication Number Publication Date
MX2020012366A true MX2020012366A (es) 2021-02-09

Family

ID=67002352

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020012366A MX2020012366A (es) 2018-05-14 2019-05-14 Biarilamidas con grupos de azucar modificados para el tratamiento de enfermedades asociadas con la trayectoria de la proteina de choque de calor.
MX2025007723A MX2025007723A (es) 2018-05-14 2019-05-14 Biarilamidas con grupos de azucar modificados para el tratamiento de enfermedades asociadas con la trayectoria de la proteina de choque de calor

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2025007723A MX2025007723A (es) 2018-05-14 2019-05-14 Biarilamidas con grupos de azucar modificados para el tratamiento de enfermedades asociadas con la trayectoria de la proteina de choque de calor

Country Status (18)

Country Link
US (2) US11827664B2 (https=)
EP (1) EP3794009A1 (https=)
JP (2) JP7508375B2 (https=)
KR (1) KR20210021457A (https=)
CN (2) CN119285591A (https=)
AU (2) AU2019271126B2 (https=)
BR (1) BR112020023277A2 (https=)
CA (1) CA3100333A1 (https=)
CL (1) CL2020002957A1 (https=)
CO (1) CO2020015380A2 (https=)
EA (1) EA202092727A1 (https=)
IL (2) IL278698B2 (https=)
MX (2) MX2020012366A (https=)
PE (1) PE20211917A1 (https=)
PH (1) PH12020551941A1 (https=)
SG (1) SG11202011311YA (https=)
UA (1) UA130486C2 (https=)
WO (1) WO2019222269A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT201900660T1 (it) 2012-02-09 2020-01-14 Univ Kansas Inibitori c-terminali di hsp90
EP3793565B1 (en) 2018-05-14 2022-01-05 Gilead Sciences, Inc. Mcl-1 inhibitors
JP7508375B2 (ja) 2018-05-14 2024-07-01 リアタ ファーマシューティカルズ インコーポレイテッド 熱ショックタンパク質経路に関連する疾患の治療のための、修飾された糖基を有するビアリールアミド
TWI778443B (zh) 2019-11-12 2022-09-21 美商基利科學股份有限公司 Mcl1抑制劑
CN114787139B (zh) 2019-11-26 2025-03-11 吉利德科学公司 用于制备mcl1抑制剂的方法和中间体
EP4247783A1 (en) 2020-11-19 2023-09-27 Gilead Sciences, Inc. Processes and intermediates for preparing macrocyclic mcl1 inhibitors
WO2023039293A1 (en) * 2021-09-13 2023-03-16 Rubedo Life Sciences, Inc. Coumarin derivatives of sugar analogs and uses thereof

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2091171A1 (en) 1990-09-07 1992-03-08 Adriano Afonso Antiviral compounds
DE19512886A1 (de) 1995-04-06 1996-10-10 Bayer Ag Substituierte Cycloalkene
FR2792320B1 (fr) 1999-04-19 2003-05-09 Hoechst Marion Roussel Inc Nouveaux amides aromatiques substitues par un ribose, leur procede de preparation et leur application comme medicaments
AU2002223127A1 (en) 2000-11-30 2002-06-11 Kissei Pharmaceutical Co., Ltd. Intellectual Property Glucopyranosyloxybenzyl benzene derivatives, medicinal compositions containing the same and intermediates in the production thereof
CA2456281A1 (en) 2001-09-21 2003-04-03 Novartis Ag Pyrane derivatives as both ace- and nep- inhibitors
US7208630B2 (en) 2004-10-27 2007-04-24 University Of Kansas Heat shock protein 90 inhibitors
US8212011B2 (en) 2004-11-03 2012-07-03 University Of Kansas Novobiocin analogues
WO2006050501A2 (en) 2004-11-03 2006-05-11 University Of Kansas Novobiocin analogues as anticancer agents
US8212012B2 (en) 2004-11-03 2012-07-03 University Of Kansas Novobiocin analogues having modified sugar moieties
US7622451B2 (en) 2004-11-03 2009-11-24 University Of Kansas Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders
US9120774B2 (en) 2004-11-03 2015-09-01 University Of Kansas Novobiocin analogues having modified sugar moieties
CA2620566A1 (en) 2005-08-30 2007-03-08 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
WO2008061108A2 (en) 2006-11-15 2008-05-22 Forest Laboratories Holdings Limited Phthalazine derivatives
DE102007002715A1 (de) * 2007-01-18 2008-07-24 Merck Patent Gmbh Triazolderivat
JP5401329B2 (ja) 2007-03-20 2014-01-29 キュリス，インコーポレイテッド Ｈｓｐ９０インヒビターとしての縮合アミノピリジン
US7960353B2 (en) 2007-05-10 2011-06-14 University Of Kansas Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders
ES2475206T3 (es) 2008-02-01 2014-07-10 Takeda Pharmaceutical Company Limited Derivados de oxima como inhibidores de HSP90
FR2928645A1 (fr) 2008-03-14 2009-09-18 Sanofi Aventis Sa Nouveaux derives de carbazole inhibiteurs d'hsp90, compositions les contenant et utilisation
US20100022635A1 (en) 2008-07-28 2010-01-28 University Of Kansas Heat shock protein 90 inhibitor dosing methods
JP5766617B2 (ja) 2009-02-20 2015-08-19 ユニバーシティ・オブ・カンザス 修飾された糖部分を有するノボビオシン類似体
US20110082098A1 (en) 2009-09-30 2011-04-07 University Of Kansas Novobiocin analogues and treatment of polycystic kidney disease
TW201216957A (en) 2010-07-13 2012-05-01 Dainippon Sumitomo Pharma Co Biarylamide derivative or a pharmaceutically acceptable salt thereof
ES2647889T3 (es) 2011-04-05 2017-12-27 Sloan-Kettering Institute For Cancer Research Inhibidores de la Hsp90
US9056104B2 (en) 2011-05-20 2015-06-16 The University Of Kansas Dynamic inhibitors of heat shock protein 90
WO2013112548A1 (en) 2012-01-23 2013-08-01 University Of South Florida Gamma-aapeptides with potent and broad-spectrum antimicrobial activity
SMT201900660T1 (it) 2012-02-09 2020-01-14 Univ Kansas Inibitori c-terminali di hsp90
US9422230B2 (en) 2013-05-09 2016-08-23 Council Of Scientific And Industrial Research Process for the preparation of an anticonvulsant agent pregabalin hydrochloride
AU2014346483B2 (en) 2013-11-07 2019-01-17 The University Of Kansas Biphenylamide derivative Hsp90 inhibitors
CA2929243C (en) 2013-11-11 2022-05-03 The University Of Kansas Coumarin based hsp90 inhibitors with urea and ether substituents
CA2951270C (en) 2014-06-13 2023-07-04 The University Of Kansas Triazole modified coumarin and biphenyl amide-based hsp90 inhibitors
MX388516B (es) * 2014-06-24 2025-03-20 Univ Kansas Bifenil amidas con grupos éter modificados como inhibidores de hsp90 e inductores de hsp70.
JP7508375B2 (ja) 2018-05-14 2024-07-01 リアタ ファーマシューティカルズ インコーポレイテッド 熱ショックタンパク質経路に関連する疾患の治療のための、修飾された糖基を有するビアリールアミド

Also Published As

Publication number Publication date
CN119285591A (zh) 2025-01-10
CO2020015380A2 (es) 2020-12-21
US20210261592A1 (en) 2021-08-26
IL278698A (https=) 2021-01-31
JP7508375B2 (ja) 2024-07-01
EP3794009A1 (en) 2021-03-24
UA130486C2 (uk) 2026-03-04
JP2021524439A (ja) 2021-09-13
AU2024267017A1 (en) 2024-12-19
SG11202011311YA (en) 2020-12-30
PH12020551941A1 (en) 2021-08-16
IL309891B1 (en) 2024-11-01
CA3100333A1 (en) 2019-11-21
IL309891A (en) 2024-03-01
US12595278B2 (en) 2026-04-07
IL278698B1 (en) 2024-02-01
KR20210021457A (ko) 2021-02-26
US20240182507A1 (en) 2024-06-06
AU2019271126B2 (en) 2024-08-29
BR112020023277A2 (pt) 2021-02-23
IL278698B2 (en) 2024-06-01
IL309891B2 (en) 2025-03-01
WO2019222269A1 (en) 2019-11-21
CL2020002957A1 (es) 2021-04-16
CN112513058A (zh) 2021-03-16
US11827664B2 (en) 2023-11-28
CN112513058B (zh) 2024-08-20
AU2019271126A1 (en) 2020-12-10
JP2024125338A (ja) 2024-09-18
MX2025007723A (es) 2025-08-01
PE20211917A1 (es) 2021-09-28
EA202092727A1 (ru) 2021-04-20

Similar Documents

Publication Publication Date Title
MX2020012366A (es) Biarilamidas con grupos de azucar modificados para el tratamiento de enfermedades asociadas con la trayectoria de la proteina de choque de calor.
CO2020013155A2 (es) Moduladores de nlrp3
MX2022013526A (es) Degradadores de proteinas y usos de los mismos.
MX2018004175A (es) Derivado oxa espiro, su metodo de preparacion, y sus aplicaciones en medicinas.
EA202090019A1 (ru) Спироциклические индолины в качестве модуляторов il-17
CL2021001395A1 (es) Compuestos derivados de panteteínas cíclicas; composición farmacéutica que los comprende; y su uso para aumentar las concentraciones de acetil-coa, para el tratamiento de cáncer, enfermedad inflamatoria, enfermedad neurodegenerativa, esclerosis múltiple, entre otras enfermedades.
CU20190073A7 (es) 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas
NZ713589A (en) Tamoxifen derivatives for treatment of neoplastic diseases, especially with high her2 protein level
CL2020000085A1 (es) Moduladores de nlrp3.
ECSP19066721A (es) Inhibidores duales de magl y faah
MX2016016294A (es) Sales de clorhidrato de n-(cianometil)-4-(2-(4-morfolinofenilamino ) pirimidin-4-il)benzamida.
CO2021014223A2 (es) Nuevos compuestos y composiciones farmacéuticas de los mismos para el tratamiento de trastornos inflamatorios
CL2018003377A1 (es) Compuestos novedosos para tratar enfermedades parasitarias. (divisional solicitud 201803187)
CO2017007325A2 (es) 2,4 diamino-quinolina sustituida como nuevos agentes anti-cancerigenos
MX2024013040A (es) Pirfenidona enriquecida con deuterio y metodos para su uso
CO2021013171A2 (es) Compuestos y composiciones como moduladores de la señalización de tlr
CL2018001631A1 (es) Compuestos de dihidroquinolinsulfonamida de alquilo
BR112021019099A2 (pt) Compostos e composições farmacêuticas dos mesmos para o tratamento de distúrbios inflamatórios
PE20150638A1 (es) Aminas ciclicas
CO2022007273A2 (es) Análogos de insulina novedosos y usos de estos
MX2019000982A (es) Compuestos y composiciones y usos de los mismos.
BR112021019110A2 (pt) Compostos e composições farmacêuticas dos mesmos para o tratamento de distúrbios inflamatórios
CY1121352T1 (el) Καινοφανες παραγωγο οξιμης χρωμονης και η χρηση του ως αλλοστερικου ρυθμιστη των μεταβοτροπικων υποδοχεων γλουταμικου
MX2020008138A (es) Formulaciones parentales y usos de estas.
ECSP22003596A (es) Moduladores del receptor de nmda